A potentially registrational Phase 2 trial of WVE-N531 to evaluate functional dystrophin expression following 24 and 48 weeks of biweekly dosing of WVE-N531
Latest Information Update: 07 Feb 2025
At a glance
- Drugs WVE-N531 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms FORWARD-53
- Sponsors WaVe life Sciences
- 13 Jan 2025 According to a Wave Life Sciences media release, study is ongoing with all patients have elected to continue treatment in the planned extension portion of the study with monthly doses of WVE-N531.
- 12 Nov 2024 According to a Wave Life Sciences media release, company expect feedback on a pathway to accelerated approval from regulators, as well as the complete 48-week FORWARD-53 data, in 1Q 2025
- 01 Oct 2024 According to a Wave Life Sciences media release, company expects data from the complete FORWARD-53 study in the first quarter of 2025 and to receive feedback from regulators on a pathway to accelerated approval.